<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METROGELÂ - metronidazoleÂ gelÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">FOR INTRAVAGINAL USE ONLY</p>
<p>NOT FOR OPHTHALMIC, DERMAL, OR ORAL USE</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">METROGEL-VAGINAL is the intravaginal dosage form of the synthetic 
antibacterial agent, metronidazole, USP at a concentration of 0.75%. 
Metronidazole is a member of the imidazole class of antibacterial agents and is 
classified therapeutically as an antiprotozoal and antiÂ­bacterial agent. 
Chemically, metronidazole is a 2-methyl-5-nitroimidazole-1-ethanol. It has a 
chemical formula of C<span class="Sub">6</span>H<span class="Sub">9</span>N<span class="Sub">3</span>O<span class="Sub">3</span>, a molecular weight of 171.16, and 
has the following structure:</p>
<p><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd3b62b6-4a80-495b-a1d3-d54eb15baf79&amp;name=chemical%20structure.jpg"></p>
<p>METROGEL-VAGINAL is a gelled, purified water solution, containing 
metronidazole at a concentration of 7.5 mg/g (0.75%). The gel is formulated at 
pH 4.0. The gel also contains carbomer 934P, edetate disodium, methyl paraben, 
propyl paraben, propylene glycol, and sodium hydroxide.</p>
<p>Each applicator full of 5 grams of vaginal gel contains approximately 37.5 mg 
of metronidazole.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<a href="http://"></a>Normal Subjects:<p class="First">Following a single, intravaginal 5 gram dose of metronidazole 
vaginal gel (equivalent to 37.5 mg of metronidazole) to 12 normal subjects, a 
mean maximum serum metronidazole concentration of 237 ng/mL was reported (range: 
152 to 368 ng/mL). This is approximately 2% of the mean maximum serum 
metronidazole concentration reported in the same subjects administered a single, 
oral 500 mg dose of metronidazole (mean C<span class="Sub">max</span>Â  = 12,785 
ng/mL, range: 10,013 to 17,400 ng/mL). These peak concentrations were obtained 
in 6 to 12 hours after dosing with metronidazole vaginal gel and 1 to 3 hours 
after dosing with oral metronidazole.</p>
<p>The extent of exposure [area under the curve (AUC)] of metronidazole, when 
administered as a single intravaginal 5 gram dose of metronidazole vaginal gel 
(equivalent to 37.5 mg of metronidazole), was approximately 4% of the AUC of a 
single oral 500 mg dose of metronidazole (4977 ng-hr/mL and approximately 
125,000 ng-hr/mL, respectively).</p>
<p>Dose-adjusted comparisons of AUCs demonstrated that, on a mg to mg comparison 
basis, the absorption of metronidazole, when administered vaginally, was 
approximately half that of an equivalent oral dosage.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Patients with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">Bacterial Vaginosis</span>:<p>Following single and multiple 5 gram doses of metronidazole 
vaginal gel to 4 patients with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>, a mean maximum serum 
metronidazole concentration of 214 ng/mL on day 1 and 294 ng/mL (range: 228 to 
349 ng/mL) on day five were reported. Steady state metroÂ­nidazole serum 
concentrations following oral dosages of 400 to 500 mg BID have been reported to 
range from 6,000 to 20,000 ng/mL.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Microbiology:<p>The intracellular targets of action of metronidazole on anaerobes 
are largely unknown. The 5-nitro group of metronidazole is reduced by 
metabolically active anaerobes, and studies have demonstrated that the reduced 
form of the drug interacts with Â­bacterial DNA. However, it is not clear whether 
interaction with DNA alone is an important component in the bactericidal action 
of metronidazole on anaerobic organisms.</p>
<p>Culture and sensitivity testing of bacteria are not routinely performed to 
establish the diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>. (See <span class="Bold"><a href="#s8">INDICATIONS AND USAGE</a></span>.)</p>
<p>Standard methodology for the susceptibility testing of the potential 
<span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> pathogens, <span class="Italics">Gardnerella vaginalis</span>, 
<span class="Italics">Mobiluncus</span> spp., and <span class="Italics">Mycoplasma 
hominis</span>, has not been defined. Nonetheless, metronidazole is an 
antimicrobial agent active <span class="Italics">in vitro</span> against most 
<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms that have been reported to be associated with 
<span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span>:</p>
<p>Â Â Â Â  <span class="Italics">Bacteroides</span> spp.<br>Â Â Â Â  <span class="Italics">Gardnerella vaginalis<br></span>Â Â Â Â  <span class="Italics">Mobiluncus</span> spp.<br>Â Â Â Â  <span class="Italics">Peptostreptococcus</span> spp.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">METROGEL-VAGINAL is indicated in the treatment of bacterial 
vaginosis (formerly referred to as <span class="Italics">Haemophilus 
</span><span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="Italics">Â­Gardnerella</span> <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, nonspecific 
<span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, <span class="Italics">Corynebacterium</span> <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>, or anaerobic 
vaginosis).</p>
<p><span class="Bold">NOTE:</span>Â For purposes of this indication, a clinical 
diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> is usually defined by the presence of a 
homogeneous <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span> that (a) has a pH of greater than 4.5, (b) emits a 
â€œfishyâ€? amine odor when mixed with a 10% KOH solution, and (c) contains clue 
cells on microscopic examination. Gramâ€™s stain results consistent with a 
diagnosis of <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> include (a) markedly reduced or absent <span class="Italics">Lactobacillus</span> morphology, (b) predominance of <span class="Italics">Gardnerella</span> morphotype, and (c) absent or few white blood 
cells.</p>
<p>Other pathogens commonly associated with <span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span>, e.g., <span class="Italics">Trichomonas vaginalis</span>, <span class="Italics">Chlamydia 
trachomatis</span>, Â­<span class="Italics">N. gonorrhoeae</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> albicans</span>, and <span class="Italics">Herpes 
simplex</span> virus should be ruled out.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">METROGEL-VAGINAL is contraindicated in patients with a prior 
history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metronidazole, parabens, other Â­ingredients of 
the formulation, or other nitroimidazole derivatives.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<a href="http://"></a><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive Seizures</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral Neuropathy</span>:<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive seizures</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, the latter 
characterized mainly by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of an extremity, have been 
reported in patients treated with oral or intravenous metronidazole. The 
appearance of abnormal neurologic signs demands the prompt discontinuation of 
metronidazole vaginal gel therapy. Metronidazole vaginal gel should be 
administered with caution to patients with central nervous system 
diseases.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic Reactions</span>:<p><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span> have been reported in alcoholic patients who 
were using oral metronidazole and disulfiram Â­concurrently. Metronidazole 
vaginal gel should not be administered to patients who have taken disulfiram 
within the last two weeks.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">METROGEL-VAGINAL affords minimal peak serum levels and systemic 
exposure (AUCs) of metronidazole compared to 500 mg oral metroÂ­nidazole dosing. 
Although these lower levels of exposure are less likely to produce the common 
reactions seen with oral metronidazole, the possibility of these and other 
reactions cannot be excluded presently. Data from well-controlled trials 
directly comparing metronidazole administered orally to metronidazole 
administered vaginally are not available.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>General:<p>Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> metabolize metronidazole 
slowly. This results in the accumulation of metronidazole and its metabolites in 
the plasma. Accordingly, for such patients, metronidazole vaginal gel should be 
administered cautiously.</p>
<p>Known or previously unrecognized <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span> may present more 
prominent symptoms during therapy with metronidazole vaginal gel. Approximately 
6-10% of patients treated with METROGEL-VAGINAL developed symptomatic <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> during or immediately after therapy.</p>
<p>Disulfiram-like reaction to alcohol has been reported with oral 
metronidazole, thus the possibility of such a reaction occurring while on 
metronidazole vaginal gel therapy cannot be excluded.</p>
<p>METROGEL-VAGINAL contains ingredients that may cause burning and irritation 
of the eye. In the event of accidental contact with the eye, rinse the eye with 
copious amounts of cool tap water.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Information for the Patient:<p>The patient should be cautioned about drinking alcohol while 
being treated with metronidazole vaginal gel. While blood levels are 
signifiÂ­cantly lower with METROGEL-VAGINAL than with usual doses of oral 
metronidazole, a possible interaction with alcohol cannot be excluded.</p>
<p>The patient should be instructed not to engage in vaginal intercourse during 
treatment with this product.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Drug Interactions:<p>Oral metronidazole has been reported to potentiate the 
anticoagulant effect of warfarin and other coumarin antiÂ­coagulants, resulting 
in a prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. This possible drug interaction should be 
considered when metronidazole vaginal gel is prescribed for patients on this 
type of anticoagulant therapy.</p>
<p>In patients stabilized on relatively high doses of lithium, short-term oral 
metronidazole therapy has been associated with elevation of serum lithium levels 
and, in a few cases, signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
<p>Use of cimetidine with oral metronidazole may prolong the half-life and 
decrease plasma clearance of metronidazole.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Drug/Laboratory Test Interactions:<p>Metronidazole may interfere with certain types of determinations 
of serum chemistry values, such as <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), 
<span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT, SGPT), lactate dehydrogenase (LDH), 
triglycerides, and glucose hexokinase. Values of zero may be observed. All of 
the assays in which interference has been reported involve enzymatic coupling of 
the assay to oxidation-reduction of nicotinamide-adenine dinucleotides (NAD + 
NADH). Interference is due to the similarity in absorbance peaks of NADH (340 
nm) and metronidazole (322 nm) at pH 7.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment of 
Fertility:<p>Metronidazole has shown evidence of carcinogenic activity in a 
number of studies involving chronic oral administration in mice and rats. 
Prominent among the effects in the mouse was the promotion of pulmonary 
tumorigenesis. This has been observed in all six reported studies in that 
species, including one study in which the animals were dosed on an intermittent 
schedule (administration during every fourth week only). At very high dose 
levels (approximately 500 mg/kg/day), there was a statistically significant 
increase in the incidence of <span class="product-label-link" type="condition" conceptid="201519" conceptname="Primary malignant neoplasm of liver">malignant liver tumors</span> in males. Also, the 
published results of one of the mouse studies indicate an increase in the 
incidence of <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphomas</span> as well as pulmonary neoplasms associated with 
lifetime feeding of the drug. All these effects are statistically significant. 
Several long-term oral dosing studies in the rat have been completed. There were 
statistically significant increases in the incidence of various neoplasms, 
particularly in mammary and hepatic tumors, among female rats administered 
metronidazole over those noted in the concurrent female control groups. Two 
lifetime tumorigenicity studies in hamsters have been performed and reported to 
be negative.</p>
<p>These studies have not been conducted with 0.75% metronidazole vaginal gel, 
which would result in significantly lower systemic blood levels than those 
obtained with oral formulations.</p>
<p>Although metronidazole has shown mutagenic activity in a number of <span class="Italics">in vitro</span> assay systems, studies in mammals (<span class="Italics">in vivo</span>) have failed to demonstrate a potential for genetic 
damage.</p>
<p>Fertility studies have been performed in mice up to six times the recommended 
human oral dose (based on mg/m<span class="Sup">2</span>) and have revealed no 
evidence of impaired fertility.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pregnancy: Teratogenic Effects:<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pregnancy Category B<p>There has been no experience to date with the use of 
METROGEL-VAGINAL in pregnant patients. Metronidazole crosses the placental 
barrier and enters the fetal circulation rapidly. No fetotoxicity or 
<span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed when metronidazole was administered orally to 
pregnant mice at six times the recommended human dose (based on mg/m<span class="Sup">2</span>); however, in a single small study where the drug was 
administered intraperitoneally, some intrauterine <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were observed. The 
relationship of these findings to the drug is unknown.<br></p>
<p>There are, however, no adequate and well-controlled studies in pregnant 
women. Because animal reproduction studies are not always predictive of human 
response, and because metronidazole is a carcinogen in rodents, this drug should 
be used during pregnancy only if clearly needed.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Nursing Mothers:<p>Specific studies of metronidazole levels in human milk following 
intravaginally administered metronidazole have not been performed. However, 
metronidazole is secreted in human milk in concentrations similar to those found 
in plasma following oral administration of metronidazole.</p>
<p>Because of the potential for tumorigenicity shown for metronidazole in mouse 
and rat studies, a decision should be made whether to discontinue nursing or to 
discontinue the drug, taking into account the importance of the drug to the 
mother.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Pediatric Use:<p>Safety and effectiveness in children have not been 
established.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<a href="http://"></a>Clinical Trials:<p class="First">There were no <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> or serious adverse events related to drug 
therapy in clinical trials involving 800 non-pregnant women who received 
METROGEL-VAGINAL.</p>
<p>In a randomized, single-blind clinical trial of 505 non-pregnant women who 
received METROGEL-VAGINAL once or twice a day, 2 patients (one from each 
regimen) discontinued therapy early due to drug-related adverse events. One 
patient discontinued drug because of moderate abdominal cramping and loose 
stools, while the other patient discontinued drug because of mild vaginal 
burning. These symptoms resolved after discontinuation of drug.</p>
<p>Medical events judged to be related, probably related, or possibly related to 
administration of METROGEL-VAGINAL once or twice a day were reported for 195/505 
(39%) patients. The incidence of individual adverse reactions were not 
significantly different between the two regimens. Unless percentages are 
otherwise stipulated, the incidence of individual adverse reactions listed below 
was less than 1%:</p>
<p>Â Â Â <span class="Italics">Â  Reproductive:</span><br>Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">Vaginal discharge</span> 
(12%),<br>Â Â Â Â  Symptomatic <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span> <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span>/<span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (10%),<br>Â Â Â Â  
Vulva/vaginal irritative symptoms (9%),<br>Â Â Â Â  Pelvic <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (3%).</p>
<p>Â Â Â Â  <span class="Italics">Gastrointestinal:</span><br>Â Â Â Â  Gastrointestinal 
<span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (7%),<br>Â Â Â Â  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (4%),<br>Â Â Â Â  Unusual taste 
(2%),<br>Â Â Â Â  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (1%),<br>Â Â Â Â  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span> 
(1%),<br>Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4023572" conceptname="Abdominal bloating">Abdominal bloating</span>/gas; thirsty, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p><span class="Italics">Â Â Â Â  Neurologic:</span><br>Â Â Â Â  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> (5%),<br>Â Â Â Â  
<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> (2%),<br>Â Â Â Â  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>.</p>
<p>Â Â Â Â  <span class="Italics">Dermatologic:<br></span>Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4172849" conceptname="Generalized pruritus">Generalized itching</span> or 
<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p><span class="Italics">Â Â Â Â  Other:<br></span>Â Â Â Â  Unspecified cramping 
(1%),<br>Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>,<br>Â Â Â Â  Darkened urine.</p>
<p>In previous clinical trials submitted for approved labeling of 
METROGEL-VAGINAL the following was also reported:</p>
<p><span class="Italics">Â Â Â Â  Laboratory:</span><br>Â Â Â Â  Increased/decreased 
white blood cell counts (1.7%).</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Other Metronidazole Formulations:<p>Other effects that have been reported in association with the use 
of <span class="Bold">topical (dermal)</span> formulations of metronidazole 
include <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, transient <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">skin erythema</span>, and mild skin dryness and 
burning. None of these adverse events exceeded an Â­incidence of 2% of 
patients</p>
<p>METROGEL-VAGINAL affords minimal peak serum levels and systemic exposure 
(AUC) of metronidazole compared to 500 mg oral metroÂ­nidazole dosing. Although 
these lower levels of exposure are less likely to produce the common Â­reactions 
seen with oral metronidazole, the possibility of these and other reactions 
cannot be excluded presently.</p>
<p>The following adverse reactions and altered laboratory tests have been 
reported with the <span class="Bold">oral or parenteral</span> use of 
metronidazole:</p>
<p><span class="Italics">Â Â Â Â  Cardiovascular: </span>Flattening of the T-wave may 
be seen in electrocardiographic tracings.<br><span class="Italics">Â Â Â Â  Central 
Nervous System:</span> (See <span class="Bold"><a href="#s10">WARNINGS</a></span>.) <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, 
<span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, 
<span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.<br><span class="Italics">Â Â Â Â  
Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, an 
unpleasant metallic taste, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, abdominal cramping, 
<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, â€œfurryâ€? tongue, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and 
modification of taste of alcoholic beverages.<br><span class="Italics">Â Â Â Â  
Genitourinary:</span> Overgrowth of CandidaÂ  in the vagina, <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">dyspareunia</span>, 
decreased libido, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>.<br><span class="Italics">Â Â Â Â  Hematopoietic:</span> 
Reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, reversible <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.<br><span class="Italics">Â Â Â Â  
<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>; erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>; nasal 
congestion; dryness of the mouth, vagina, or vulva; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; fleeting 
<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pains</span>.<br><span class="Italics">Â Â Â Â  Renal:</span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, 
<span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, a sense of pelvic pressure, darkened urine.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There is no human experience with overdosage of metronidazole 
vaginal gel. Vaginally applied metronidazole gel,Â  0.75% could be absorbed in 
sufficient amounts to produce systemic effects. (See <span class="Bold"><a href="#s10">WARNINGS</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose is one applicator full of METROGEL-VAGINAL 
(approximately 5 grams containing approximately 37.5 mg of metronidazole) 
intravaginally once or twice a day for 5 days. For once a day dosing, 
METROGEL-VAGINAL should be administered at bedtime.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">METROGEL-VAGINAL (metronidazole vaginal gel) 0.75% Vaginal Gel is 
supplied in a 70 gram tube and packaged with 5 vaginal applicators.</p>
<p>70 gram tubeÂ Â Â Â Â Â  NDC 54868-3110-0.</p>
<p>Store at controlled room temperature 15Â° to 30Â°C (59Â° to 86Â°F). Protect from 
freezing.</p>
<a href="http://"></a><a href="http://"></a><a href="http://"></a>Clinical Studies<p>In a randomized, single-blind clinical trial of non-pregnant 
women with <span class="product-label-link" type="condition" conceptid="4303258" conceptname="Bacterial vaginosis">bacterial vaginosis</span> who received METROGEL-VAGINAL daily for 5 days, 
the clinical cure rates for evaluable patients determined at 4 weeks after 
completion of therapy for the QD and BID regimens were 98/185 (53%) and 109/190 
(57%), respectively.</p>
<p><span class="Bold">Rx only</span></p>
<a name="i18bebbf2-cb45-429a-81ca-701f97fba479"></a><table width="100%"><tbody class="Headless">
<tr class="First">
<td><span class="Bold">Manufactured for</span></td>
<td><span class="Bold">Manufactured by</span></td>
<td><span class="Bold">Relabeling of "Additonal" barcode label by</span></td>
</tr>
<tr>
<td>Graceway Pharmaceuticals, LLC<br>
</td>
<td>DPT Laboratories, Inc.<br>
</td>
<td>Physicians Total Care, Inc.<br>
</td>
</tr>
<tr class="Last">
<td>Bristol, TNÂ Â Â Â  37620<br>
</td>
<td>San Antonio, TXÂ Â Â  78215<br>
</td>
<td>Tulsa, OKÂ Â Â Â Â  74146<br>
</td>
</tr>
</tbody></table>
<p><br></p>
<p>July 2009</p>
<p>129108<br></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-12"></a><p></p>
<a href="http://"></a>INFORMATION FOR PATIENTS SECTION<p class="First">MetroGel-Vaginal<span class="Sup">Â®</span><br>(metronidazole 
vaginal gel)<br>0.75% Vaginal Gel</p>
<p><span class="Bold">DIRECTIONS FOR USE</span></p>
<p><span class="Bold">1.Â  Filling the applicator</span></p>
<ul>
<li>Remove cap and puncture metal seal on tube with the pointed tip of cap. (See 
Figure 1) </li>
<li>Screw end of applicator onto tube. (See Figure 2) </li>
<li>
<span class="Italics">Gently</span> squeeze the tube from the <span class="Italics">bottom </span>to fill applicator. Plunger will stop when the 
applicator is full. (See Figure 3) </li>
<li>Unscrew applicator and replace cap on tube.</li>
</ul>
<a name="i1062fe8a-43a6-45a6-8eb3-0190d9abb91f"></a><table width="40%"><tbody class="Headless">
<tr class="First">
<td><img alt="image of figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd3b62b6-4a80-495b-a1d3-d54eb15baf79&amp;name=Figure%201.jpg"></td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td><img alt="image of figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd3b62b6-4a80-495b-a1d3-d54eb15baf79&amp;name=Figure%202.jpg"></td>
<td><br></td>
</tr>
<tr>
<td><br></td>
<td><br></td>
</tr>
<tr>
<td><img alt="image of figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd3b62b6-4a80-495b-a1d3-d54eb15baf79&amp;name=Figure%203.jpg"></td>
<td><br></td>
</tr>
<tr class="Last">
<td><br></td>
<td><br></td>
</tr>
</tbody></table>
<br><p><span class="Bold">2.Â  Inserting the applicator</span></p>
<ul>
<li><p class="First">The applicator may be inserted while lying on your back with your 
knees bent or in any comfortable position.</p></li>
<li><p class="First">Hold filled applicator by barrel, and gently insert into vagina 
as far as it will comfortably go. (See Figure 4)</p></li>
<li><p class="First">Slowly press the plunger until it stops to deposit gel into 
vagina and then withdraw the applicator.</p></li>
</ul>
<a name="ibdcae93c-866d-40f3-808a-86b7704f5c6c"></a><table width="40%"><tbody class="Headless">
<tr class="First"><td><br></td></tr>
<tr class="Last"><td><img alt="image of figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd3b62b6-4a80-495b-a1d3-d54eb15baf79&amp;name=Figure%204.jpg"></td></tr>
</tbody></table>
<br><p><span class="Bold">3. Care of the applicator</span></p>
<p>If physician prescribes twice-a-day dosing:</p>
<ul>
<li><p class="First">After use, pull the plunger out of the barrel. (See Figure 
5)</p></li>
<li><p class="First">Wash both plunger and barrel in warm soapy water and rinse 
thoroughly.</p></li>
<li><p class="First">To reassemble applicator, gently push plunger back into 
barrel.</p></li>
</ul>
<div class="Figure"><img alt="image of figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd3b62b6-4a80-495b-a1d3-d54eb15baf79&amp;name=Figure%205.jpg"></div>
<p><span class="Bold">IMPORTANT<br></span>For once-a-day dosing, apply one 
applicator full at bedtime. For twice-a-day dosing, apply one applicator full 
each morning and evening for five days, or as directed by physician.</p>
<p><span class="Bold">WARNINGS</span></p>
<ul>
<li><p class="First">If significant irritation develops from the use of this 
medication, discontinue use and consult your physician.</p></li>
<li><p class="First">Do not use during pregnancy except under the supervision of a 
physician.</p></li>
<li><p class="First">Keep this and all medications out of reach of children.</p></li>
<li><p class="First">For vaginal use only. Not for use in the eyes, on the skin or in 
the mouth.</p></li>
</ul>
<p>Store at room temperature. Avoid exposure to extreme heat or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>. <br>See 
end of carton and bottom of tube for lot number and expiration date.</p>
<p>US patent #s 4,837,378; 5,536,743<br>Other patents pending</p>
<p>Manufactured for:<br>Graceway Pharmaceuticals, LLC<br>Bristol, TN 
37620<br>By:<br>DPT Laboratories, Inc.<br>San Antonio, TX 78215</p>
<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">MetroGel-Vaginal<span class="Sup">Â®</span>(metronidazole vaginal 
gel)<br>0.75% Vaginal Gel<br></span>with 5 applicators<br><span class="Italics"><span class="Bold"><span class="Italics">FOR INTRAVAGINAL USE ONLY. 
(NOT FOR OPHTHALMIC, DERMAL, OR ORAL USE.)</span></span><br><span class="Bold">Rx 
Only</span><br>Net Wt. 70g</span></p>
<p>NDC 54868-3110-0</p>
<p><img alt="image of package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bd3b62b6-4a80-495b-a1d3-d54eb15baf79&amp;name=3110.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METROGELÂ 		
					</strong><br><span class="contentTableReg">metronidazole gel</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3110(NDC:29336-200-25)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">VAGINAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METRONIDAZOLE</strong> (METRONIDAZOLE) </td>
<td class="formItem">METRONIDAZOLE</td>
<td class="formItem">7.5Â mg Â inÂ 1Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOMER 934</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3110-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">70 g in 1 TUBE, WITH APPLICATOR</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020208</td>
<td class="formItem">12/19/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>51046537-1147-43b7-9b0a-140919c1453b</div>
<div>Set id: bd3b62b6-4a80-495b-a1d3-d54eb15baf79</div>
<div>Version: 1</div>
<div>Effective Time: 20110331</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
